Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.12530/25075| Title: | Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain. | |
| Authors: | ||
| Keywords: | ||
| Issue Date: | 2016 | |
| Citation: | Clinicoecon Outcomes Res.2016;(8):475-484 | |
| Abstract: | To evaluate the cost-effectiveness of obinutuzumab in combination with chlorambucil (GClb) versus rituximab plus chlorambucil (RClb) in the treatment of adults with previously untreated chronic lymphocytic leukemia (CLL) and with comorbidities that make them unsuitable for full-dose fludarabine-based therapy, from the perspective of the Spanish National Health System. | |
| PMID: | 27703384 | |
| URI: | https://hdl.handle.net/20.500.12530/25075 | |
| Rights: | openAccess | |
| ISSN: | 1178-6981 | |
| Appears in Collections: | Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos Fundaciones e Institutos de Investigación > IIS H. U. La Princesa > Artículos | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| PMC5036824.pdf | 929.65 kB | Adobe PDF |  View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.